Schizophrenia is a chronic and severe mental disorder which affects the patients’ thinking ability. People suffering with schizophrenia, may have difficulty in understanding the different between what is real and what is imaginary. Additionally, people suffering from this illness, need to follow a long term treatment to get effective results. Mostly schizophrenia occurs to the population aged from 16 to 30 years. In rare cases, children too are diagnosed with schizophrenia.
Although the causes of Schizophrenia are still unclear, but some suggest that the cause of this disease include genetics, biology, possible viral infections, and immune disorders. It can be recognized if any one shows symptoms such as, hallucination, delusion, and abnormal behavior.
The schizophrenia market growth is majorly attributed to the increasing patient population suffering with this disease. According to WHO, in 2016, more than 21 million people around the world were diagnosed with schizophrenia. Additionally people with schizophrenia have 2-2.5 % more chances to die earlier than the general population.
A research study published in WHO, in 2016, stated that schizophrenia is more common among males in comparison to females, around 12 million men and 9 million women were diagnosed with schizophrenia.
Moreover, uses of evidence-based technical guidance, tools and training packages for expanding the services in the developing countries are adding fuel to the schizophrenia market. However, majority of the people with this disease in the developing countries are unable to get the treatment owing to lack of effective structure for the treatment in mental hospitals. Increase in number of patients seeking treatment and the rising demand for improved healthcare infrastructure are expected to drive the market.
Get a sample report at https://www.marketresearchfuture.com/sample_request/1625 .
The global schizophrenia market is segmented on the basis of by diagnosis, by treatment type, and by end user.
On the basis of the diagnosis, it is segmented into blood and urine tests, brain imaging, vision testing, and others.
On the basis of the treatment type, it is segmented into surgery, radiation therapy, medications, and others.
On the basis of the end user, it is segmented into hospitals, clinics, diagnostic centers, rehabilitation centers and others.
The Americas dominate the global schizophrenia market owing to better treatment availability, high healthcare expenditure, and increasing government support for research & development. Furthermore, strict rule introduce by WHO, will leads the market of schizophrenia.
Europe holds the second position in the global schizophrenia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain which is poised to propel the schizophrenia market.
Asia Pacific is the fastest growing schizophrenia market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, WHO’s Mental Health Gap Action Programme, launched in 2008, uses evidence-based technical guidance, tools and training packages to expand service especially in the developing countries like India, Iran, Pakistan, Tanzania. Furthermore, WHO initiative for training primary health-care personnel, providing access to essential drugs, and supporting families in providing home care lead the market growth of the schizophrenia in the region.
On the other hand, in the Middle East and Africa, blood disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.
Some of key the players in the market are Minerva Neurosciences (U.S.), Promentis Pharmaceuticals, Inc. (U.S.), Bristol-Myers Squibb (U.S.), PsychoGenics Inc. (U.S.), Vineuro Pharmaceuticals, Novartis AG (Switzerland), Merz Pharma GmbH & Co. KGaA (Germany), AbbVie Inc. (U.S.), Eli-Lilly and Company (U.S.), AstraZeneca Plc (U.K)
Browse complete report at https://www.marketresearchfuture.com/reports/schizophrenia-market-1625 .
LIST OF TABLES
Table 1 Schizophrenia Market Industry Synopsis, 2017-2023
Table 2 Global Schizophrenia Market Estimates And Forecast, 2017-2023, (USD Million)
Table 3 Global Schizophrenia Market By Region, 2017-2023, (USD Million)
Table 4 Global Schizophrenia Market By Diagnosis, 2017-2023, (USD Million)
Table 5 Global Schizophrenia Market By Treatment Type, 2017-2023, (USD Million)
Table 6 Global Schizophrenia Market By End Users, 2017-2023, (USD Million)
Table 7 North America Schizophrenia Market By Diagnosis, 2017-2023, (USD Million)
Table 8 North America Schizophrenia Market By Treatment Type, 2017-2023, (USD Million)